Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon's Healthy Moves (India)

This article was originally published in PharmAsia News

Executive Summary

Indian biopharmaceutical producer, Biocon, saw its stock climb an impressive 27 percent in the past month. Of that figure, 13 percent was accumulated in just the last week. Analysts attribute the share jump to the company's positive second-quarter returns, reported on Oct. 18. Biocon's consolidated revenue rose 12.5 percent. Much of this rise was due to improvements in the company's contract research and manufacturing services (CRAMS) business, including its subsidiaries, Syngene and Clinigene. That sector of the company skyrocketed 44 percent. Still, analysts say the CRAMS business is undervalued. Biocon hopes to remedy that fact by separately listing its subsidiaries. In the future, Biocon hopes to focus on its immunosuppresant, and insulin products. To this end, the company sold its enzyme business to Noyozymes South Asia for $115 million. Aside from the good performance and the enzyme divestment, analysts say the company's intention to list internationally was also a big factor in its stock increase. A final boost was given by the recent approval of the company's breast cancer treatment, Abraxane (paclitaxel), by the Drug Controller General of India. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel